Biotech News

Paratek Pharmaceuticals Announces Positive Top Line Data from Pilot Efficacy Study for the Treatment of Pulmonary Anthrax and Acceptance of the Second Procurement of NUZYRA® (omadacycline) under BARDA Project BioShield

Paratek Pharmaceuticals (PRTK)Paratek Pharmaceuticals2022-12-19 07:30 ESTClinical readout

100% Survival Rate in Anthrax-infected Rabbits Treated with Omadacycline

Total Revenue Recognition to Paratek of $38.1 Million

BOSTON, Dec. 19, 2022 (GLOBE NEWSWIRE) --...

Paratek Pharmaceuticals

Paratek Pharmaceuticals is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.

Recent company news

PRTKParatek Pharmaceuticals2026-04-16 07:30 EST

Paratek Pharmaceuticals to Present New Data on NUZYRA® (omadacycline) at ESCMID Global 2026

PRTKParatek Pharmaceuticals2026-03-18 07:00 EST

Paratek Pharmaceuticals Completes Combination with Radius Health, Expanding Its Multi-Product Specialty Commercial Platform

PRTKParatek Pharmaceuticals2026-02-24 07:30 EST

Paratek Pharmaceuticals Announces Positive Results for NUZYRA® Therapeutic Efficacy Studies in Inhalation Anthrax Triggering Additional Procurement under BARDA Project BioShield Contract

PRTKParatek Pharmaceuticals2025-10-17 07:30 EST

Paratek Pharmaceuticals to Present New Data on NUZYRA® (omadacycline) at IDWeek 2025 and CHEST 2025

PRTKParatek Pharmaceuticals2025-05-21 08:26 EST

Paratek Pharmaceuticals Completes Acquisition of Optinose, Creating an Expanded Portfolio of Specialty Therapies

Stock data

Close: —
Market cap: —
Exchange: NASDAQ
Sector: Biopharma
Location: United States